Kung-Chu Ho1, Cheng-Hong Toh2, Shih-Hong Li3, Chien-Ying Liu3, Cheng-Ta Yang3, Yu-Jen Lu4, Tzu-Pei Su1, Chih-Wei Wang5, Tzu-Chen Yen6,7. 1. Department of Nuclear Medicine, Chang Gung Memorial Hospital and Chang Gung University, Keelung, Taiwan. 2. Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 3. Department of Thoracic Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 4. Department of Neurosurgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 5. Department of Anatomic Pathology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 6. Department of Nuclear Medicine and Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital and Chang Gung University, 5 Fu-Shin Street, Kueishan, Taoyuan, 333, Taiwan. yentc1110@gmail.com. 7. Department of Nuclear Medicine, Xiamen Chang Gung Hospital, Xiamen, Fujian, China. yentc1110@gmail.com.
Abstract
PURPOSE: The role of brain FDG-PET in patients with lung cancer and brain metastases remains unclear. Here, we sought to determine the prognostic significance of whole-body PET/CT plus brain PET/MR in predicting the time to neurological progression (nTTP) and overall survival (OS) in this patient group. METHODS: Of 802 patients with non-small cell lung cancer who underwent primary staging by a single-day protocol of whole-body PET/CT plus brain PET/MR, 72 cases with adenocarcinoma and brain metastases were enrolled for a prognostic analysis of OS. On the basis of the available follow-up brain status, only 52 patients were eligible for prognostic analysis of nTTP. Metastatic brain tumors were identified on post-contrast MR imaging, and the tumor-to-brain ratio (TBR) was measured on PET images. RESULTS: Multivariate analysis revealed that FDG-PET findings and eligibility for initial treatment with targeted therapy were significant independent predictors of nTTP and OS. A new index, termed the molecular imaging prognostic (MIP) score, was proposed to define three disease classes. MIP scores were significant predictors of both nTTP and OS (P < 0.001). Pre-existing prognostic indices such as Lung-molGPA scores were significant predictors of OS but did not predict nTTP. CONCLUSIONS: When staging is performed with whole-body PET/CT plus brain PET/MR, our new prognostic index may be helpful to stratify the outcomes of patients with lung adenocarcinoma and brain metastases. The superior prognostic power of this index for nTTP might be used to select appropriate patients for intracranial control and thereby achieve better quality of life.
PURPOSE: The role of brain FDG-PET in patients with lung cancer and brain metastases remains unclear. Here, we sought to determine the prognostic significance of whole-body PET/CT plus brain PET/MR in predicting the time to neurological progression (nTTP) and overall survival (OS) in this patient group. METHODS: Of 802 patients with non-small cell lung cancer who underwent primary staging by a single-day protocol of whole-body PET/CT plus brain PET/MR, 72 cases with adenocarcinoma and brain metastases were enrolled for a prognostic analysis of OS. On the basis of the available follow-up brain status, only 52 patients were eligible for prognostic analysis of nTTP. Metastatic brain tumors were identified on post-contrast MR imaging, and the tumor-to-brain ratio (TBR) was measured on PET images. RESULTS: Multivariate analysis revealed that FDG-PET findings and eligibility for initial treatment with targeted therapy were significant independent predictors of nTTP and OS. A new index, termed the molecular imaging prognostic (MIP) score, was proposed to define three disease classes. MIP scores were significant predictors of both nTTP and OS (P < 0.001). Pre-existing prognostic indices such as Lung-molGPA scores were significant predictors of OS but did not predict nTTP. CONCLUSIONS: When staging is performed with whole-body PET/CT plus brain PET/MR, our new prognostic index may be helpful to stratify the outcomes of patients with lung adenocarcinoma and brain metastases. The superior prognostic power of this index for nTTP might be used to select appropriate patients for intracranial control and thereby achieve better quality of life.
Authors: J Lee Villano; Eric B Durbin; Chris Normandeau; Jigisha P Thakkar; Valentina Moirangthem; Faith G Davis Journal: Neuro Oncol Date: 2014-06-02 Impact factor: 12.300
Authors: Mauricio E Diaz; Maciej Debowski; Craig Hukins; David Fielding; Kwun M Fong; Catherine S Bettington Journal: J Med Imaging Radiat Oncol Date: 2018-05-10 Impact factor: 1.735
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Francesco Fraioli; Nicholas J Screaton; Samuel M Janes; Thida Win; Leon Menezes; Irfan Kayani; Rizwan Syed; Fulvio Zaccagna; Celia O'Meara; Anna Barnes; Jamshed B Bomanji; Shonit Punwani; Ashley M Groves Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-15 Impact factor: 9.236
Authors: Petra Hoffknecht; Amanda Tufman; Thomas Wehler; Theo Pelzer; Rainer Wiewrodt; Martin Schütz; Monika Serke; Jan Stöhlmacher-Williams; Angela Märten; Rudolf Maria Huber; Nicolas J Dickgreber Journal: J Thorac Oncol Date: 2015-01 Impact factor: 15.609